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Cancer has been characterized as a constellation of hundreds of diseases differing in underlying
mutations and depending on cellular environments. Carcinogenesis as a stochastic physical process
has been studied for over sixty years, but there is no accepted standard model. We show that
the hazard rates of all cancers are characterized by a simple dynamic stochastic process on a half-
line, with a universal linear restoring force balancing a universal simple Brownian motion starting
from a universal initial distribution. Only a critical radius defining the transition from normal to
tumorigenic genomes distinguishes between different cancer types when time is measured in cell-
cycle units. Reparametrizing to chronological time units introduces two additional parameters: the
onset of cellular senescence with age and the time interval over which this cessation in replication
takes place. This universality implies that there may exist a finite separation between normal cells
and tumorigenic cells in all tissue types that may be a viable target for both early detection and
preventive therapy.
PACS numbers: 87.19.xj, 89.75.Fb, 87.14.gk
Cancer is considered to be a multifaceted disease where
the phenotypic similarities of tumor progression are a ve-
neer over a multitude of possible underlying genetic al-
terations [1]. Three-quarters of all cancers are probably
sporadic. As an organism ages, the accumulation of mu-
tations increases the likelihood of alteration in an onco-
gene or in a tumor suppressor gene, which in turn can
lead to an accumulation of mutations. The process of
carcinogenesis has been modeled for over 60 years [2–14],
but there is no consensus model. Summaries of the state
of cancer incidence modeling can be found in Harding,
Pompei and Wilson [15] and Beerenwinkel et al. [16].
Recently, Tomasetti and Vogelstein [17] showed that
the lifetime risk of cancers of many different types is cor-
related with the total number of divisions of the normal
self-renewing cells, the somatic stem cells, that maintain
each tissue’s homeostasis. This implies that most cancer
is due to random mutations arising during DNA repli-
cation in normal, noncancerous somatic stem cells. This
observation poses an interesting challenge for a mechanis-
tic understanding of cancer incidence. If a somatic stem
cell can become cancerous at any time during a lifetime,
any valid model of carcinogenesis should be able to use
this as a basis for age-specific cancer hazard rate pre-
diction and match available age-specific cancer incidence
rates[18].
Harding et al. [15] have analyzed the Surveillance,
Epidemiology and End Results (SEER[18], specifically
SEER 9) cancer registries to compile age-specific inci-
dence rates, with particular care accorded to the data on
the very elderly (ages > 80 years). They noted that inci-
dence for most cancers reached a maximum between ages
75 years and 90 years, with a precipitous decline later,
and often tended to vanish among centenarians. This de-
cline is difficult to explain in stem cell models that assume
that any stem cell will eventually produce a tumor [13].
With exceptions, for example, the beta model [6] and the
generalized beta model [12], such models project increas-
ing cancer rates throughout adulthood.
Our aim here is to present a simple universal physical
model for the stochastic process of tumorigenesis that re-
solves the tension between the spontaneous random ori-
gin of cancer shown in Ref. [17] and observed age-specific
incidence rate curves [15, 18]. While tissues are hetero-
geneous in cellular characteristics, recent work on induc-
ing pluripotency[20] in differentiated cells[19], along with
work on somatic stem cells with regard to cancer[21],
suggests that such stem cells share commonalities. If so,
the fundamental process of cellular replication, and the
fidelity of the concomitant information propagation, is
most likely to be universal. From a physical perspec-
tive, the propagation of information by replication is a
stochastic process with error correction in the form of
a multitude of repair mechanisms[25]. We expect, then,
that a limit on error correction should be universal to all
cancers in a given species. In other words, irrespective of
tissue or cell type, we expect that there should be a co-
ordinate, measuring the effective error in the propagated
genome, that at a critical value marks a sharp transition
between normal and tumor cells. If there is no such sharp
transition, the utility and feasibility of early detection of
cancer is called into question. Here, we show that that
there is such a coordinate, and a universal diffusion pro-
cess for the position of each stem cell on this coordinate,
such that age-specific cancer hazard rates are determined
by the probability of crossing a cancer–type–independent
error limit. Diffusion processes have been studied in this
connection[26], but the focus was on the accumulation
of mutations in the pre-cancer phase. The role of error
correction in computing cancer incidence rates has not
been investigated.
We set out to compare possible diffusive processes for
different tissues. Although DNA mutations and epige-
netic changes can be introduced into a non–mitotic cell,
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2(e.g. through a viral insertion or the action of retro-
transposons), we focus on the errors that accumulate dur-
ing cell division (i.e. S phase). The human genome has
3 × 109 base pairs that can mutate but not all genome
positions contribute equally to cancer susceptibility. We
introduce an effective error coordinate, r, parameterizing
an appropriately weighted mean alteration distance in
genome space, including both mutations and epigenetic
changes, such as methylation changes that affect DNA
repair genes themselves. We hypothesized that cancer
occurs when this error coordinate exceeds a critical value,
rc.
The cell constantly expends energy for DNA error cor-
rection, which acts as a restoring force to oppose mu-
tational diffusion [25]. We choose a restoring force that
scales linearly with error coordinate. The error coor-
dinate therefore obeys an Ornstein-Uhlenbeck stochastic
process [22] on the half line. There are two physical moti-
vations for this choice of restoring force: First, the error
correction response is then tolerant of infinitesimal ex-
cursions away from the original genome, and second, a
discrete urn model of mutating bases has this process as
a scaling limit.
The probability density for r obeys the Fokker-Planck
equation
∂τp(r, τ) = r
−2
θ ∂rrp(r, τ) + ∂
2
rp(r, τ) (1)
with a reflecting boundary condition at the origin (i.e.
∂rp(r = 0, τ) = 0). This equation can be analytically
solved. We allow for the possibility of mitotic mutations
during prenatal development by parameterizing the ini-
tial density as n(r, τ = 0) ∝ exp(−αr2/2r2θ), where α is
dimensionless and α =∞ for an error free initial genome.
Given that we only consider error accumulation during
mitosis, the relevant time scale is measured in terms of
the number of cell divisions, which may not be constant
in time. In fact, it is well known that cells become senes-
cent with age. Hence, to relate τ to chronological time t,
we introduce a reparameterization
dτ = dt D(t) ≡ dt 0.5
(
1 + tanh
(Ts − t
ws
))
, (2)
where Ts is a cell–type specific senescence time, and ws
a cell–type specific senescence time uncertainty, moti-
vated by Ref. [15]. The probability of having become
cancerous is given by p(r > rc) =
∫∞
rc
p(s, t)ds. The can-
cer hazard rate is then the time derivative of the odds
p(r > rc)/p(r < rc):
I(t) =
d
dt
∫∞
rc
ds p(s, t)∫ rc
0
ds p(s, t)
(3)
Hazard rates are better estimated from incidence[18]
rather than mortality data[15].
The model is specified by the parameters α, rθ, Ts,
ws and rc. Our goal is to fit the predicted cancer haz-
ard rate to the observed incidence rates for various can-
cer types[18]. However, since we are free to choose a
scale to measure errors, we can fix rθ = 1. Using Nelder-
Mead minimization for parameter determination, we only
needed to fit the incidence curve I(t) up to a scale fac-
tor since our theory considers the per–stem–cell hazard
rate while the total hazard rate is this rate summed in-
dependently over all stem cells in the tissue [17]. If there
are only x susceptible cells in the tissue, then the hazard
rate for that tissue is x times the rate for a single somatic
stem cell in that tissue.
Expressing the cancer-specific values of α as rα ≡
rθ/
√
α, we found that the best fit rc and rα values for
all cancers depended on cancer type weakly (Table 1).
The average rc value was 2.6 and the mean width of
the initial distribution was rα = 0.22. The Bayes In-
formation Criterion (BIC) can be used to compare mod-
els taking model complexity into account. The BIC for
a model with rα = 0.16 fixed for all tumor types was
BICα = 1.75×104 while that for models with cancer–type
specific initial distributions was BIC0 = 2.092×104. Some
examples are shown in Fig. 1. Thus, notwithstanding the
fact that the initial distribution is tissue and cell-type-
specific, as proliferation during development is heteroge-
neous and different tissues undergo tissue-specific repli-
cation and apoptosis cycles, the model selected by the
BIC is the one with a universal initial distribution. Of
course, cell proliferation during growth and development
in children and adults are controlled differently, and our
results apply only to tumorigenesis in adults. With two
exceptions (a subtype of Hodgkin lymphoma and testic-
ular cancer), the senescence time was very long, on the
order of 90 years. For these two exceptions, the time
interval, ws, over which the somatic stem cells in these
tissues stop dividing was much longer.
We tried to simplify the model further by fixing rc
and rα for all tumor types and the resulting model with
fixed rc = 4.4 and rα = 0.26 reached a BIC value of
BICα,c = 2.087 × 104. This value is slightly less than
BIC0 for the model with rc, rα both optimized for each
tumor type. Thus, surprisingly, we find that genomic dif-
fusion, error correction, the initial error distribution, and
the critical error radius, are largely universal factors with
regards to the incidence of cancer in somatic stem cells
in all tissues. The only factors that are mostly cancer
specific are the senescence age and the time interval over
which senescence occurs. With a finer categorization of
cancer types, and more precise knowledge of the num-
ber of somatic stem cells relevant for each cancer type,
it should be possible to determine parameters more pre-
cisely by including the scale of the coordinate distribu-
tion in the optimization, as rc and rα are obviously not
completely independent.
The inability of some previous models [7] to match in-
3FIG. 1. Cancer incidence rates. Models with all parame-
ters fitted (Full) and those with rα = 0.16 are almost indis-
tinguishable. Incidence is measured per 105 person-years at
risk.
cidence rates that peak and then decrease led Ref. [15] to
suggest some possible resolutions. The resolution embod-
ied in our model is that there is a DNA error–correcting
process so that every stem cell does not, in fact, pro-
ceed to carcinogenesis given enough time, and that senes-
cence correlates the reduction in tumorigenesis with the
reduction in mitosis. Indeed, Ref. [15] explicitly argued
that tissue and cellular senescence are the likely biological
mechanisms for the observed drop off in cancer incidence
in the very elderly. The beta model [6] is also consistent
with the latter part of the resolution, but does not have
a dynamic basis nor does it posit a role for DNA repair.
DNA repair involves a multitude of different proteins
in distinct pathways [25]. It is remarkable that the sum
total end result of all these repair mechanisms attempt-
ing to correct random mutations is apparently a linear
stochastic restoring force. Apart from a constant force,
this is the simplest possible functional form. We spec-
ulate that a constant restoring force would require an
inordinate energetic effort for even innocuous mutations,
whereas a linear restoring force allows a graduated es-
calation in repair effort based on the effective error co-
ordinate. Tolerance to low levels of mutation has also
been suggested to be necessary for evolution [27]. This
seems to support our linear restoring force, but with the
caveat that cancers mostly arise from somatic stem cells
whereas evolution is due to germline mutations and the
error correction mechanisms need not be the same for
the two cell types. However, it may be the case that a
linear restoring force confers higher fitness in both cases
although for different reasons.
In conclusion, the simple physical understanding we
have presented here suggests that the space of mutational
histories has a natural diffusion away from the initial
starting distribution, restrained by a universal error cor-
rection, and starting from a universal initial distribution.
The incidence rate for all cancers is the rate of moving be-
yond a threshold that depends weakly on tumor type. A
relatively sharp demarcation between tumors and normal
cells is a concrete prediction of our model of tumorige-
nesis. This universality suggests that reducing the inci-
dence of sporadic cancers requires enhancing mechanisms
that maintain the fidelity of DNA replication in somatic
stem cells throughout a lifetime. While this is a facile ob-
servation, the universality we found suggests that there
are not a multitude of strategies required on a tissue–
by–tissue basis. More importantly, there is an interval
between rθ = 1 and rc ≈ 2.6 for almost all cancers where
the mutated somatic stem cell genome has not yet be-
come tumorigenic, and yet may be distinguishable from
a normal stem cell, since the initial genome distribution
has a width rα ≈ 0.2. Detecting somatic stem cells in
this interval early, and then targeting therapies towards
ablating them, is a possible approach to reducing the inci-
dence of cancer. The universality we have found provides
a measure of hope that there may be tissue–independent
commonalities in both detection and therapy that could
prevent metastases.
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5TABLE I. Parameters for various cancers (NS, Nervous Sys-
tem; (non-)Hodgkin, (non-)Hodgkin Lymphoma)
Tissue Sex BIC Ts(yrs) ws(yrs) rα rc
All M 418 93.7 14.2 0.119 2.68
Brain & NS M 45.6 90.3 7.15 0.259 2.5
Breast M 67.7 97.7 0.515 0.151 2.5
Colon M 178 98 7.32 0.247 2.88
Esophagus M 29.4 92.8 14.2 0.1 2.59
Hodgkin1 M 14.4 6.18e-08 32.8 0.159 1.19
Hodgkin2 M 129 90.2 12.7 0.1 2.25
Kidney M 1e+04 92.3 13 0.1 2.38
Larynx M 110 80.6 16.3 0.166 2.86
Leukemia M 342 103 2.7 0.269 2.83
Liver M 290 94.6 9.4 0.199 2.34
Lung M 120 88.5 14.8 0.181 3.02
Melanoma M 150 97.5 5.01 0.229 2.29
Mesothelioma M 50.2 87.4 7.33 0.285 3.97
Misc M 80.3 99.5 3.93 0.219 3.08
Myeloma M 18.5 96 9.22 0.183 2.65
Non-Hodgkin M 76.2 97.1 9.67 0.194 2.57
Oral M 501 98.5 7.86 0.1 1.98
Pancreas M 22.8 96.9 7.52 0.261 2.89
Prostate M 2.48e+03 74.7 22.9 0.1 3.51
Stomach M 33.5 99.5 5.95 0.256 2.88
Testis M 33.4 28.9 20.1 0.135 1.59
Thyroid M 23.9 87.2 12.2 0.242 1.9
Urinary M 2.68e+03 97.2 9.04 0.182 2.89
All F 2.01e+03 99.9 13.4 0.197 2.4
Brain & NS F 38.1 92.4 6.85 0.327 2.5
Breast F 1.64e+03 91 30.3 0.1 2.2
Cervix Uteri F 204 96.7 7.66 0.103 1.33
Colon F 51.6 100 10.4 0.228 2.91
Corpus Uteri F 516 81.1 19.1 0.1 2.43
Esophagus F 18.4 99.3 5.79 0.282 2.87
Hodgkin1 F 13.4 3.12e-09 22.4 0.142 1.37
Hodgkin2 F 124 93 12.1 0.1 2.19
Kidney F 50.9 93 11 0.214 2.46
Leukemia F 192 102 4.63 0.308 2.9
Lung F 36.8 82.7 14 0.12 3.08
Misc F 57.2 107 5.01 0.428 3.5
Non-Hodgkin F 113 97.3 9.88 0.222 2.65
Larynx F 18.6 71.9 16.7 0.365 3.91
Liver F 24.9 92 12.8 0.1 2.69
Melanoma F 19.8 102 3.19 0.226 1.7
Mesothelioma F 15.6 90 4.51 0.187 3.04
Myeloma F 49.8 92.3 7.35 0.275 2.99
Oral F 32.4 99.4 5.52 0.235 2.39
Ovary F 269 96.6 9.21 0.211 2.27
Pancreas F 24.3 103 14 0.1 2.77
Stomach F 140 106 3.48 0.173 2.72
Thyroid F 20.8 80.7 23.6 0.113 1.28
Urinary F 45.2 98.8 5.6 0.251 2.72
